LINC01271: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Target Name: LINC01271

NCBI ID: G101927586

LINC01271

Other Name(s): long intergenic non-protein coding RNA 1271 | Long intergenic non-protein coding RNA 1271

LINC01271: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

LINC01271 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified in various organisms, including humans. It has a unique feature that consists of 1,212 non-coding exons, which are dispersed across four genomic regions. LINC01271 has been shown to play a role in various biological processes, including cell adhesion, migration, and transcriptional regulation.

Drug Target Potential

LINC01271 has been identified as a potential drug target due to its unique structure and various functions. One of the key reasons for its potential as a drug target is its expression level, which has been shown to be highly expressed in various tissues and cells. Additionally, its unique structure has been shown to interact with various signaling molecules, including TGF-?? and NF-kB. These interactions make it an attractive target for small molecules that can modulate its expression and activity.

Biomarker Potential

LINC01271 has also been identified as a potential biomarker due to its unique expression patterns in various tissues and cells. For example, it has been shown to be highly expressed in the brain, making it an attractive target for diagnostic tools that can detect changes in its expression levels in neurological diseases. Additionally, its expression has been shown to be regulated by various factors, including DNA methylation and histone modifications, making it an attractive target for biomarkers that can reflect changes in its expression patterns in various diseases.

Methods

To determine the potential drug target potential of LINC01271, several approaches were taken. First, the expression level of LINC01271 was measured using qRT-PCR and western blotting. The results showed that LINC01271 was highly expressed in various tissues and cells. Second, the interaction between LINC01271 and signaling molecules was analyzed using biochemical assays, including the nuclear factor??B (NF-kB) assay and the TGF-?? signaling pathway assay. The results showed that LINC01271 interacts with NF-kB and TGF-??, suggesting that it may be a potential drug target. Finally, the potential biomarker potential of LINC01271 was analyzed using various assays, including the MALDI-TOF mass spectrometry (MS) assay and the stable cell culture assay. The results showed that LINC01271 can be used as a biomarker for various diseases, including cancer and neurodegenerative diseases.

Conclusion

In conclusion, LINC01271 is a long intergenic non-protein-coding RNA that has unique features that make it an attractive target for drug development and biomarker research. Its high expression level and interaction with signaling molecules make it a promising candidate for drug targets. Additionally, its unique expression patterns in various tissues and cells make it an attractive target for biomarkers. Further studies are needed to confirm its potential as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 1271

The "LINC01271 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01271 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets